We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Surgery More Effective Than Nonsurgical Treatment for Spinal Stenosis

By HospiMedica staff writers
Posted on 06 Mar 2008
A new study reports that surgery for the relief of symptoms associated with lumbar spinal stenosis offered a significant advantage over nonsurgical treatment in terms of pain relief and functional improvement, an improvement that was maintained at 2 years follow-up. More...


Researchers at Dartmouth Medical School (Hanover, NH, USA) conducted a multicenter trial known as the Spine Patient Outcomes Research Trial (SPORT), which included patients from 13 medical centers in the United States with multidisciplinary spine practices. The study included a randomized cohort of 289 patients and a concurrent observational cohort of 365 subjects who opted not to be randomized. In the randomized cohort, 138 patients were assigned to surgery and 151 to nonsurgical treatment. Study interventions included standard posterior decompressive laminectomy or usual care, which was recommended to include, at least, active physical therapy, education, or counseling with home exercise instruction, and the administration of nonsteroidal anti-inflammatory drugs (NSAIDs) if possible. The effect of treatment was defined as the difference in the mean change from baseline between the surgical group and the nonsurgical group.

The researchers reported that the as-treated analysis, which combined both cohorts and adjusted for potential confounders, showed a significant advantage for surgery by 3 months for all primary outcomes, which remained significant at 2 years. They also reported that the treatment effect for surgery was seen as early as 6 weeks, appeared to peak at 6 months, and persisted for 2 years. However, there was only moderate improvement among patients in the nonsurgical group during the 2-year study period; additionally, after two years, 67% of patients who were randomly assigned to surgery had undergone surgery, and 43% of those who were randomly assigned to receive nonsurgical care had crossed over and received surgical treatment. The study was published in the February 21, 2008, issue of The New England Journal of Medicine (NEJM).

"Patients with spinal stenosis without degenerative spondylolisthesis who underwent surgery showed significantly greater improvement in pain, function, satisfaction, and self-rated progress than did patients who were treated nonsurgically,” concluded lead author James N. Weinstein, M.Sc., D.O., and colleagues.


Related Links:
Dartmouth Medical School

Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Surgical Headlight
IsoTorch
Ultrasound Needle Guidance System
SonoSite L25
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The researchers grew pancreatic tissue (above) so it incorporated a mesh-like electronic network (red). Cells within the tissue produce insulin (green). (Photo courtesy of Penn Medicine)

‘Cyborg’ Transplants Could Replace Pancreatic Tissue Damaged by Diabetes

Type 1 diabetes destroys insulin-producing islet cells, forcing patients to rely on lifelong insulin therapy or scarce organ transplants. Although lab-grown pancreatic tissue offers a promising alternative,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.